Neuroscience & CNS
Part of Biotech - Drug Development
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 BIIB | Biogen Inc. Common Stock | $27.5b | $174.55 | -1.6% | 413.3K |
 NBIX | Neurocrine Biosciences Inc | $12.9b | $130.88 | -0.5% | 613.6K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $11.5b | $31.68 | +2.8% | 72.6K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $11.3b | $186.56 | -0.2% | 132.9K |
 AXSM | Axsome Therapeutics, Inc | $8.2b | $168.82 | +0.2% | 44.7K |
 CYTK | Cytokinetics Inc. | $7.8b | $65.72 | -1.5% | 301.2K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $7.7b | $314.18 | +1.2% | 84.1K |
 PTCT | PTC Therapeutics, Inc. | $5.4b | $69.78 | +3.0% | 135.5K |
 XENE | Xenon Pharmaceuticals Inc | $5.3b | $56.56 | -0.5% | 1.0M |
 TGTX | TG Therapeutics, Inc. | $5.0b | $35.03 | +4.5% | 489.3K |
 ALKS | Alkermes Inc. plc | $5.0b | $34.36 | -1.4% | 612.9K |
 ACAD | Acadia Pharmaceuticals Inc. | $3.6b | $22.59 | +1.7% | 427.2K |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $3.5b | $30.64 | +0.6% | 130.2K |
 DNLI | Denali Therapeutics Inc. Common Stock | $2.9b | $19.70 | -4.6% | 388.9K |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.8b | $51.03 | +1.1% | 67.0K |
 ALMS | Alumis Inc. Common Stock | $2.6b | $22.25 | -4.8% | 323.5K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.9b | $32.83 | +0.3% | 129.2K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $1.7b | $20.30 | -1.8% | 299.5K |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $1.6b | $27.71 | -0.1% | 249.0K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $1.4b | $15.71 | +5.0% | 423.1K |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $1.3b | $33.97 | +1.2% | 53.1K |
 ATAI | AtaiBeckley Inc. Common Stock | $1.2b | $3.87 | +2.0% | 946.5K |
 BHVN | Biohaven Ltd. | $1.2b | $9.47 | -3.3% | 250.1K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.2b | $4.70 | +7.4% | 2.3M |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.0b | $32.67 | +1.1% | 85.9K |
 GHRS | GH Research PLC Ordinary Shares | $0.8b | $15.10 | +3.6% | 16.9K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $0.8b | $21.91 | +3.5% | 37.0K |
 TBPH | Theravance Biopharma, Inc. | $0.8b | $16.18 | +1.0% | 181.7K |
 ANNX | Annexon, Inc. Common Stock | $0.7b | $5.72 | +4.1% | 779.0K |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.7b | $74.50 | +4.3% | 19.9K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $6.97 | -0.3% | 206.6K |
 LBRX | LB Pharmaceuticals Inc Common Stock | $0.7b | $25.63 | -0.2% | 75.2K |
 ANRO | Alto Neuroscience Inc. | $0.6b | $21.47 | -0.9% | 67.6K |
 PRTA | Prothena Corporation plc Ordinary Shares | $498.0m | $9.96 | +1.1% | 78.1K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $493.1m | $4.14 | +0.4% | 189.5K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $465.2m | $13.20 | -1.8% | 17.5K |
 VNDA | Vanda Pharmaceuticals Inc. | $393.1m | $6.96 | -0.6% | 205.9K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $328.0m | $2.02 | +0.8% | 355.0K |
 OVID | Ovid Therapeutics Inc. Common Stock | $318.7m | $2.27 | +3.4% | 2.4M |
 NGEN | NervGen Pharma Corp. Common stock | $295.5m | $4.39 | +3.0% | 31.5K |
 PEPG | PepGen Inc. Common Stock | $292.4m | $1.76 | +2.0% | 882.7K |
 AVXL | Anavex Life Sciences | $261.3m | $3.06 | +2.2% | 207.0K |
 ACIU | AC Immune SA | $260.5m | $2.77 | +0.4% | 22.8K |
 NERV | Minerva Neurosciences, Inc | $258.3m | $5.11 | -3.2% | 55.8K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $230.6m | $3.98 | +0.4% | 252.9K |
 ALEC | Alector, Inc. Common Stock | $222.9m | $2.42 | +0.2% | 265.0K |
 HELP | Cybin Inc. Common Stock | $215.5m | $5.32 | +3.9% | 278.6K |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $208.6m | $1.78 | -0.8% | 165.4K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $205.6m | $3.21 | +4.4% | 662.0K |
 NTHI | NeOnc Technologies Holdings, Inc. Common Stock | $171.6m | $5.96 | +0.3% | 18.8K |